<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ometendo</journal-id><journal-title-group><journal-title xml:lang="ru">Ожирение и метаболизм</journal-title><trans-title-group xml:lang="en"><trans-title>Obesity and metabolism</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2071-8713</issn><issn pub-type="epub">2306-5524</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/2071-8713-5122</article-id><article-id custom-type="elpub" pub-id-type="custom">ometendo-5122</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Первичный идиопатический гиперальдостеронизм в клинической практике</article-title><trans-title-group xml:lang="en"><trans-title>Primary idiopathic hyperaldosteronism in clinical practice</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Molashenko</surname><given-names>N V</given-names></name></name-alternatives><email xlink:type="simple">molashenko@mail.ru</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Troshina</surname><given-names>E A</given-names></name></name-alternatives><email xlink:type="simple">troshina@inbox.ru</email></contrib></contrib-group><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>15</day><month>12</month><year>2012</year></pub-date><volume>9</volume><issue>4</issue><issue-title>№4 (2012)</issue-title><fpage>3</fpage><lpage>9</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Molashenko N.V., Troshina E.A., 2012</copyright-statement><copyright-year>2012</copyright-year><copyright-holder xml:lang="ru">Molashenko N.V., Troshina E.A.</copyright-holder><copyright-holder xml:lang="en">Molashenko N.V., Troshina E.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.omet-endojournals.ru/jour/article/view/5122">https://www.omet-endojournals.ru/jour/article/view/5122</self-uri><abstract><p>Первичный гиперальдостеронизм (ПГА) – клинический синдром, развивающийся в результате избыточной продукции альдостерона клубочковой зоной коркового вещества надпочечников, при котором секреция альдостерона полностью или частично автономна по отношению к ренин-ангиотензиновой системе, что обусловливает развитие низкорениновой артериальной гипертензии (АГ). Первичный идиопатический гиперальдостеронизм (ПИГА) – один из вариантов в структуре синдрома ПГА. Частота ПИГА составляет, по различным оценкам, от 20 до 55% больных ПГА. Морфологическим субстратом ПИГА является двусторонняя мелко- или крупноузелковая гиперплазия надпочечников. В статье представлены современные данные о патогенезе, клинической картине, диагностике и лечении первичного идиопатического гиперальдостеронизма.</p></abstract><trans-abstract xml:lang="en"><p>Primary hyperaldosteronism (PHA) is a clinical syndrome that develops as a result of excess production of aldosterone by adrenal glomerular zone, where aldosterone secretion is completely or partially autonomous in relation to the renin-angiotensin system. This factor leads to the development low renin arterial hypertension (AH). Primary idiopathic hyperaldosteronism is one of the forms of PHA. The prevalence of this form is variously estimated from 20 to 55% of patients with PHA. Morphological substrate primary idiopathic hyperaldosteronism is a bilateral micro- or macronodular adrenal hyperplasia. This article summarizes the contemporary view of the pathogenesis, clinical presentation, diagnosis and treatment of idiopathic hyperaldosteronism.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>гиперальдостеронизм</kwd><kwd>альдостерон</kwd><kwd>ренин</kwd><kwd>спиронолактон</kwd><kwd>эплеренон</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Бельцевич Д.Г. (перевод). Первичный гиперальдостеронизм. Клинические рекомендации. Эндокринная хирургия 2008;2(3):6–10.</mixed-citation><mixed-citation xml:lang="en">Бельцевич Д.Г. (перевод). Первичный гиперальдостеронизм. Клинические рекомендации. Эндокринная хирургия 2008;2(3):6–10.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Мельниченко Г.А. Эндокринология. Национальное руководство. М.: ГЭОТАР-Медиа, 2009. 685 с.</mixed-citation><mixed-citation xml:lang="en">Дедов И.И., Мельниченко Г.А. Эндокринология. Национальное руководство. М.: ГЭОТАР-Медиа, 2009. 685 с.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Калинин А.П., Майстренко Н.А. Хирургия надпочечников. М.: Медицина, 2000.</mixed-citation><mixed-citation xml:lang="en">Калинин А.П., Майстренко Н.А. Хирургия надпочечников. М.: Медицина, 2000.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Кеттайл В.М., Арки Р.А. Патофизиология эндокринной системы. Пер. с анг. СПб.-М.: «Невский Диалект» – «Издательство БИНОМ», 2001:115–118.</mixed-citation><mixed-citation xml:lang="en">Кеттайл В.М., Арки Р.А. Патофизиология эндокринной системы. Пер. с анг. СПб.-М.: «Невский Диалект» – «Издательство БИНОМ», 2001:115–118.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Левитская З.И., Вабищевич А.А., Перистая Е.В. Первичный идиопатический гиперальдостеронизм в клинической перспективе. Лечащий врач 2006;2:18–19.</mixed-citation><mixed-citation xml:lang="en">Левитская З.И., Вабищевич А.А., Перистая Е.В. Первичный идиопатический гиперальдостеронизм в клинической перспективе. Лечащий врач 2006;2:18–19.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Трошина Е.А., Бельцевич Д.Г., Молашенко Н.В. Диагностика и дифференциальная диагностика первичного гиперальдостеронизма. Клиническая медицина 2009;5:15–20.</mixed-citation><mixed-citation xml:lang="en">Трошина Е.А., Бельцевич Д.Г., Молашенко Н.В. Диагностика и дифференциальная диагностика первичного гиперальдостеронизма. Клиническая медицина 2009;5:15–20.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Фадеев В.Ф., Бельцевич Д.Г., Рогаль Е.Ю., Молашенко Н.В., Мельниченко Г.А. Лечение гиперальдостеронизма. Проблемы эндокринологии 2010;3:42–44.</mixed-citation><mixed-citation xml:lang="en">Фадеев В.Ф., Бельцевич Д.Г., Рогаль Е.Ю., Молашенко Н.В., Мельниченко Г.А. Лечение гиперальдостеронизма. Проблемы эндокринологии 2010;3:42–44.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Чихладзе Н.М., Чазова И.Е. Симптоматические артериальные гипертонии. Диагностика и лечение. М.: Медицина, 2005.</mixed-citation><mixed-citation xml:lang="en">Чихладзе Н.М., Чазова И.Е. Симптоматические артериальные гипертонии. Диагностика и лечение. М.: Медицина, 2005.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">An Endocrine Society Clinical Practice Guidelines. Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism. J Clin. Endocrinol. Metab 2008;93:3266–3281.</mixed-citation><mixed-citation xml:lang="en">An Endocrine Society Clinical Practice Guidelines. Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism. J Clin. Endocrinol. Metab 2008;93:3266–3281.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Brilla C., Matsubara L., Weber K. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary aldosteronism. J Mol. Cell. Cardiol 1993;25:563–575.</mixed-citation><mixed-citation xml:lang="en">Brilla C., Matsubara L., Weber K. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary aldosteronism. J Mol. Cell. Cardiol 1993;25:563–575.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Brilla C.G. Aldosterone and myocardial fibrosis in heart failure. Herz 2000;25:299–306.</mixed-citation><mixed-citation xml:lang="en">Brilla C.G. Aldosterone and myocardial fibrosis in heart failure. Herz 2000;25:299–306.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Brilla C.G., Janicki J.S., Weber K.T. Impaired diastolic function and coronary reserve in genetic hypertension role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. American Heart Association. Circulation Research 1991;69:107–115.</mixed-citation><mixed-citation xml:lang="en">Brilla C.G., Janicki J.S., Weber K.T. Impaired diastolic function and coronary reserve in genetic hypertension role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. American Heart Association. Circulation Research 1991;69:107–115.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Brilla C.G., Pick R., Tan L.B., Janicki J.S., Weber K.T. Remodeling of the rat right and left ventricles in experimental hypertension. Circ. Res 1990;67:1355–1364.</mixed-citation><mixed-citation xml:lang="en">Brilla C.G., Pick R., Tan L.B., Janicki J.S., Weber K.T. Remodeling of the rat right and left ventricles in experimental hypertension. Circ. Res 1990;67:1355–1364.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Calhoun D.A., Sharma K. The role of aldosteronism in causing obesity-related cardiovascular risk. Cardiol Clin 2010 Aug;28(3):517–27.</mixed-citation><mixed-citation xml:lang="en">Calhoun D.A., Sharma K. The role of aldosteronism in causing obesity-related cardiovascular risk. Cardiol Clin 2010 Aug;28(3):517–27.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Chapman D., Weber K.T., Eghbali M. Regulation of fibrillar collagen types I and III and basement membrane type IV collagen gene expression in pressure overloaded rat myocardium. Circ. Res 1990; 67:787–794.</mixed-citation><mixed-citation xml:lang="en">Chapman D., Weber K.T., Eghbali M. Regulation of fibrillar collagen types I and III and basement membrane type IV collagen gene expression in pressure overloaded rat myocardium. Circ. Res 1990; 67:787–794.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Chhokar V.S., Sun Y., Bhattacharya S.K., Ahokas R.A., Myers L.K., Xing Z., Smith R.A., Gerling I.C., Weber K.T. Loss of bone minerals and strength in rats with aldosteronism. Am J. Physiol. Heart. Circ. Physiol 2004 Nov;287(5):H2023–6.</mixed-citation><mixed-citation xml:lang="en">Chhokar V.S., Sun Y., Bhattacharya S.K., Ahokas R.A., Myers L.K., Xing Z., Smith R.A., Gerling I.C., Weber K.T. Loss of bone minerals and strength in rats with aldosteronism. Am J. Physiol. Heart. Circ. Physiol 2004 Nov;287(5):H2023–6.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Chitalia N., Weeg N., Antonios T.F.T. Aldosterone-producing adrenal adenoma and idiopathic intracranial hypertension – a pathogenetic link for aldosterone? QJM 2010;103:699–702.</mixed-citation><mixed-citation xml:lang="en">Chitalia N., Weeg N., Antonios T.F.T. Aldosterone-producing adrenal adenoma and idiopathic intracranial hypertension – a pathogenetic link for aldosterone? QJM 2010;103:699–702.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Gaddam K., Corros C, Pimenta E. et al. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension 2010 May;55(5):1137–42. Epub. 2010, Mar 29.</mixed-citation><mixed-citation xml:lang="en">Gaddam K., Corros C, Pimenta E. et al. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension 2010 May;55(5):1137–42. Epub. 2010, Mar 29.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Garthwaite S.M., McMahon E.G. The evolution of aldosterone antagonists. Mol. Cel. Endocrinol 2004;217:27–31.</mixed-citation><mixed-citation xml:lang="en">Garthwaite S.M., McMahon E.G. The evolution of aldosterone antagonists. Mol. Cel. Endocrinol 2004;217:27–31.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Griffing G.T., McIntosh T., Berelowitz B., Hudson M., Salzman R., Manson J.A., Melby J.C. Plasma beta-endorphin levels in primary aldosteronism. J Clin. Endocrinol. Metab 1985 Feb;60(2):315–9.</mixed-citation><mixed-citation xml:lang="en">Griffing G.T., McIntosh T., Berelowitz B., Hudson M., Salzman R., Manson J.A., Melby J.C. Plasma beta-endorphin levels in primary aldosteronism. J Clin. Endocrinol. Metab 1985 Feb;60(2):315–9.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Fallo F., Della Mea P., Sonino N. et al. Adiponectin and insulin sensitivity in primary aldosteronism. American Journal of Hypertension 2007;20(8):855–861.</mixed-citation><mixed-citation xml:lang="en">Fallo F., Della Mea P., Sonino N. et al. Adiponectin and insulin sensitivity in primary aldosteronism. American Journal of Hypertension 2007;20(8):855–861.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Fallo F., Federspil G., Veglio F, Mulatero P. The metabolic syndrome in primary aldosteronism. Curr Diab Rep 2008 Feb;8(1):42–7.</mixed-citation><mixed-citation xml:lang="en">Fallo F., Federspil G., Veglio F, Mulatero P. The metabolic syndrome in primary aldosteronism. Curr Diab Rep 2008 Feb;8(1):42–7.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Fallo F., Veglio F., Bertello C. et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin. Endocrin. Metabol 2006;91(2):454–459.</mixed-citation><mixed-citation xml:lang="en">Fallo F., Veglio F., Bertello C. et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin. Endocrin. Metabol 2006;91(2):454–459.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Funder J.W., Carey R.M., Fardella C., Gomez-Sanchez C.E., Mantero F., Stowasser M., Young W.F. Jr., Montori V.M., Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol. Metab 2008 Sep;93(9):3266–81.</mixed-citation><mixed-citation xml:lang="en">Funder J.W., Carey R.M., Fardella C., Gomez-Sanchez C.E., Mantero F., Stowasser M., Young W.F. Jr., Montori V.M., Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol. Metab 2008 Sep;93(9):3266–81.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Iacobellis G., Petramala L., Cotesta D. et al. Adipokines and cardiometabolic profile in primary hyperaldosteronism. J Clin. Endocrinol. Metab 2010 May;95(5):2391–8. Epub 2010 Mar 1.</mixed-citation><mixed-citation xml:lang="en">Iacobellis G., Petramala L., Cotesta D. et al. Adipokines and cardiometabolic profile in primary hyperaldosteronism. J Clin. Endocrinol. Metab 2010 May;95(5):2391–8. Epub 2010 Mar 1.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Jeon J.H., Kim K.Y., Kim J.H. et al. A novel adipokine CTRP1 stimulates aldosterone production. FASEB Journal 2008;22:1502–1511.</mixed-citation><mixed-citation xml:lang="en">Jeon J.H., Kim K.Y., Kim J.H. et al. A novel adipokine CTRP1 stimulates aldosterone production. FASEB Journal 2008;22:1502–1511.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Karagiannis A., Tziomalos K., Papageorgiou A., Kakafika A.I., Pagourelias E.D., Anagnostis P., Athyros V.G., Mikhailidis D.P. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin. Pharmacother 2008 Mar;9(4):509–15.</mixed-citation><mixed-citation xml:lang="en">Karagiannis A., Tziomalos K., Papageorgiou A., Kakafika A.I., Pagourelias E.D., Anagnostis P., Athyros V.G., Mikhailidis D.P. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin. Pharmacother 2008 Mar;9(4):509–15.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Lastra-Lastra G., Sowers J.R., Restrepo-Erazo C. et al. Role of Aldosterone and angiotensin II in Insulin Resistance: An Update. Clin. Endocrinol 2009;71:1–6.</mixed-citation><mixed-citation xml:lang="en">Lastra-Lastra G., Sowers J.R., Restrepo-Erazo C. et al. Role of Aldosterone and angiotensin II in Insulin Resistance: An Update. Clin. Endocrinol 2009;71:1–6.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Menard J., Gonzalez M.F., Guyene T.T., Bissery A. Investigation of aldosterone-synthase inhibition in rats. J Hypertens 2006;24:1147–1155.</mixed-citation><mixed-citation xml:lang="en">Menard J., Gonzalez M.F., Guyene T.T., Bissery A. Investigation of aldosterone-synthase inhibition in rats. J Hypertens 2006;24:1147–1155.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Mulatero P., Morello F., Veglio F. Genetics of primary aldosteronism. J Hypertens 2004;22:663–670.</mixed-citation><mixed-citation xml:lang="en">Mulatero P., Morello F., Veglio F. Genetics of primary aldosteronism. J Hypertens 2004;22:663–670.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Perraudin V., Delarue C., Lefebvre H., Do Rego J.L., Vaudry H., Kuhn J.M. Evidence for a role of vasopressin in the control of aldosterone secretion in primary aldosteronism: in vitro and in vivo studies. J Clin. Endocrinol. Metab 2006 Apr;91(4):1566–72. Epub 2006 Jan 31.</mixed-citation><mixed-citation xml:lang="en">Perraudin V., Delarue C., Lefebvre H., Do Rego J.L., Vaudry H., Kuhn J.M. Evidence for a role of vasopressin in the control of aldosterone secretion in primary aldosteronism: in vitro and in vivo studies. J Clin. Endocrinol. Metab 2006 Apr;91(4):1566–72. Epub 2006 Jan 31.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Stehr C.B., Mellado R, Ocaranza MP, et al. Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. J Hypertens 2010 Oct;28(10):2120–6.</mixed-citation><mixed-citation xml:lang="en">Stehr C.B., Mellado R, Ocaranza MP, et al. Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. J Hypertens 2010 Oct;28(10):2120–6.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Takeda Y., Furukawa К., Inaba S. et al. Genetic Analysis of Aldosterone Synthase in Patients with Idiopathic Hyperaldosteronism. J Clin Endocrinol Metab l999;84(5):1633–1637.</mixed-citation><mixed-citation xml:lang="en">Takeda Y., Furukawa К., Inaba S. et al. Genetic Analysis of Aldosterone Synthase in Patients with Idiopathic Hyperaldosteronism. J Clin Endocrinol Metab l999;84(5):1633–1637.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Tian Y., Balla Т., Baukal A.J. et al. Growth responses to angiotensin II in bovine adrenal glomerulosa cells. Am J Physiol (Endocrinol) 1995;268:135–144.</mixed-citation><mixed-citation xml:lang="en">Tian Y., Balla Т., Baukal A.J. et al. Growth responses to angiotensin II in bovine adrenal glomerulosa cells. Am J Physiol (Endocrinol) 1995;268:135–144.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Urbanet R., Pilon C., Calcagno A. et al. Analysis of insulin sensitivity in adipose tissue of patients with primary aldosteronism. J Clin. Endocrinol. Metab 2010 Aug;95(8):4037–42. Epub., 2010 May 19.</mixed-citation><mixed-citation xml:lang="en">Urbanet R., Pilon C., Calcagno A. et al. Analysis of insulin sensitivity in adipose tissue of patients with primary aldosteronism. J Clin. Endocrinol. Metab 2010 Aug;95(8):4037–42. Epub., 2010 May 19.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Weber K. Aldosterone and spironolactone in heart failure. N. Engl. J. Med 1999;341:753–5.</mixed-citation><mixed-citation xml:lang="en">Weber K. Aldosterone and spironolactone in heart failure. N. Engl. J. Med 1999;341:753–5.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Weber K. Aldosterone in congestive heart failure. N. Engl. J. Med 2001;345:1689–97.</mixed-citation><mixed-citation xml:lang="en">Weber K. Aldosterone in congestive heart failure. N. Engl. J. Med 2001;345:1689–97.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Weber K.T., Singh K.D., Hey J.C. Idiopathic intracranial hypertension with primary aldosteronism: report of 2 cases. Am J Med Sci 2002 Jul;324(1):45–50.</mixed-citation><mixed-citation xml:lang="en">Weber K.T., Singh K.D., Hey J.C. Idiopathic intracranial hypertension with primary aldosteronism: report of 2 cases. Am J Med Sci 2002 Jul;324(1):45–50.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Whaley-Connell A., Johnson M.S., Sowers J.R. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog. Cardiovasc. Dis 2010 Mar-Apr;52(5):401–9.</mixed-citation><mixed-citation xml:lang="en">Whaley-Connell A., Johnson M.S., Sowers J.R. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog. Cardiovasc. Dis 2010 Mar-Apr;52(5):401–9.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Wong G.W., Krawczyk S.A., Kitidis-Mitrokostas C., Revett T., Gimeno R., Lodish H.F. Molecular, biochemical and functional characterizations of C1q/TNF family members: adipose-tissue-selective expression patterns, regulation by PPAR-γ agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions. Biochem J 2008 Dec;416(2):161–77</mixed-citation><mixed-citation xml:lang="en">Wong G.W., Krawczyk S.A., Kitidis-Mitrokostas C., Revett T., Gimeno R., Lodish H.F. Molecular, biochemical and functional characterizations of C1q/TNF family members: adipose-tissue-selective expression patterns, regulation by PPAR-γ agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions. Biochem J 2008 Dec;416(2):161–77</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Young W.F. Primary aldosteronism: renaissance of a syndrome. Clin. Endocrinol. (Oxf) 2007;66:607–618.</mixed-citation><mixed-citation xml:lang="en">Young W.F. Primary aldosteronism: renaissance of a syndrome. Clin. Endocrinol. (Oxf) 2007;66:607–618.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Young W.F.Jr., William F. Minireview: Primary Aldosteronism – Changing Concepts in Diagnosis and Treatment. Endocrinology 2003 Jun;144(6):2208–13.</mixed-citation><mixed-citation xml:lang="en">Young W.F.Jr., William F. Minireview: Primary Aldosteronism – Changing Concepts in Diagnosis and Treatment. Endocrinology 2003 Jun;144(6):2208–13.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
